![]() An indirect comparison suggests that guselkumab is as effective as the biological DMARDs secukinumab and ixekizumab, particularly for skin symptoms.įor people who have had 2 conventional DMARDs and at least 1 biological DMARD, guselkumab's cost-effectiveness estimates are within the range that NICE normally considers an acceptable use of NHS resources.įor people who have had 2 conventional DMARDs and for whom TNF-alpha inhibitors are contraindicated, the costs and benefits are similar to those of other treatments recommended by NICE. Guselkumab is a biological DMARD.Ĭlinical evidence shows that guselkumab is effective compared with placebo, but it has not been compared directly with other biological DMARDs for treating psoriatic arthritis. Many of these are already recommended by NICE for treating psoriatic arthritis. ![]() People with active psoriatic arthritis that is not controlled well enough with 2 conventional DMARDs are usually offered biological DMARDs. Why the committee made these recommendations People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. ![]() 1.5 These recommendations are not intended to affect treatment with guselkumab that was started in the NHS before this guidance was published.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |